Binod Dhakal, MD, on Benefit of Cilta-Cel in Earlier Lines of Multiple Myeloma Treatment
The associate professor at Medical College of Wisconsin discussed current studies evaluating cilta-cel and ongoing research.
“Compared to standard of care, cilta-cel has been shown to provide some very efficacious responses with a manageable safety profile in patients who are lenalidomide-refractory and the PFS benefit was seen in all high-risk subgroups. Cilta-cel led to deep and durable responses and its use in earlier lines improved tolerability than when used in later lines. So, all this data suggests that in patients who are lenalidomide-refractory after the first relapse, this can be a new standard of care option for patients.
Janssen and Legend Biotech’s chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene ciloleucel (cilta-cel) yielded higher rates of progression-free survival (PFS) in patients with relapsed multiple myeloma after lenalidomide compared with standard of care (SOC) therapies.1 Marketed as Carvykti, the therapy is approved for patients after 4 lines of therapy, but Legend recently submitted a supplemental biologics license application for cilta-cel in the earlier line indication.2
The updated data from the CARTITUDE-4 study (NCT04181827) were presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, held June 2-6, in Chicago, Illinois, by Binod Dhakal, MD, associate professor, Medical College of Wisconsin. CGTLive spoke with Dhakal to learn more about the potential of cilta-cel in earlier lines of therapy for multiple myeloma. He discussed his experience treating patients with Carvykti in the clinic and how the field is adapting to using CAR T-cell therapy for hematologic malignancies. He also shared further research being conducted with the therapy and his anticipation for updated data from other CARTITUDE studies.
Click here for more coverage of ASCO 2023.
